← All Researchers
Jia Ruan
Professor of Clinical Medicine
Weill Cornell Medicine · New York, United States
About
Developed the lenalidomide-rituximab regimen as a chemotherapy-free frontline approach for MCL, particularly relevant for elderly patients.
Specialties
Novel agentsLenalidomideFrontline therapy
Key Trials
Lenalidomide-rituximab frontline MCL
Publications (3)
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
Leukemia & lymphoma · Jan 1, 2024